The in vitro activity of teicoplanin, a new antibiotic related to vancomycin, was determined against 456 gram-positive cocci. The activity of teicoplanin in comparison with that of vancomycin was similar against staphylococci but 4 to 40 times higher against enterococci and I8-hemolytic and viridans streptococci. The single-dose pharmacokinetics of teicoplanin were studied in six healthy volunteers after administration of 3 and 6 mg/kg intravenously and of 3 mg/kg intramuscularly. The kinetic parameters after both intravenous doses were very similar. The curves for concentration in plasma for the 3-and 6-mg/kg intravenous doses showed a triexponential decline with elimination half-lives of 47.3 and 44.1 h, respectively. The percentages of the doses recovered in urine (0 to 102 h) were 43.2 and 44.1%, respectively. The areas under the plasma curves were dose related: 256.5 and 520.9 ,tg/h per ml, respectively. The bioavailability of teicoplanin after injection of 3 mg/kg intramuscularly was 90%, and the peak level was 7.1 ,ug/ml. The mean levels in plasma 24 h after the 3-mg/kg doses were 2.1 and 2.3 ,ug/ml, respectively, and the mean level in plasma 24 h after the 6-mg/kg intravenous dose was 4.2 ,ug/ml.
Teicoplanin is a glycopeptide antibiotic related to vancomycin and ristocetin. It has formerly been described as teichomycin A2, one of the major components of a complex of antibiotics produced by Actinoplanes teichomyceticus nov. sp. ATCC 31121 (1, 16) . Teicoplanin is active in vitro and in vivo against gram-positive microorganisms (2, 5, 7, 8, 11, 12, 14, 15, 18) . Teicoplanin interferes with cell wall biosynthesis by inhibiting polymerization of peptidoglycan, a mode of action very similar to that of vancomycin (17) . This study reports the comparative in vitro activity of teicoplanin on a large number of gram-positive clinical isolates and the results of single-dose pharmacokinetics of teicoplanin in young healthy volunteers after intravenous and intramuscular administration.
MATERIALS AND METHODS Antibiotics. Teicoplanin was supplied by Gruppo Lepetit Spa, Milan, Italy. The other reference antibiotics were obtained from the following firms: ampicillin and oxacillin, Beecham Research Laboratories; penicillin G, Continental Pharma; and vancomycin and erythromycin, Eli Lilly Research Laboratories.
Bacterial strains. Recent isolates were collected from clinical specimens submitted to the Diagnostic Microbiology Laboratory. The isolates were identified by conventional methods and distributed as follows: 216 Staphylococcus aureus, 73 Staphylococcus epidermidis, and 167 Streptococcus spp. strains, including 34 Streptococcus faecalis, 18 Streptococcus pneumoniae, 18 Streptococcus pyogenes, 18 Streptococcus agalactiae, 21 Streptococcus milleri, 21 Streptococcus sanguis (biotypes I and II), 13 Streptococcus mitis, 9 Streptococcus salivarius, and 5 Streptococcus mutans strains. The Staphylococcus aureus strains were subdivided into penicillin-susceptible strains (MIC c 0.25 ,ug/ml), penicillin-resistant but oxacillin-susceptible strains (MIC s 2 ,ug/ml), and oxacillin-resistant strains (MIC > 2 p,g/ml).
Susceptibility test. Isolates were tested for susceptibility by agar dilution in Diagnostic Sensitivity Test agar (Oxoid) * Corresponding author.
with inocula of 105 to 106 CFU per spot delivered by a multipoint inoculator. Growth of the streptococci (except for Streptococcus faecalis) was supported with 5% lysed horse blood added to the medium. The antibiotics were tested in twofold serial dilutions at concentrations ranging from 0.004 to 128 ,ug/ml. The plates were incubated overnight at 36°C, except those containing oxacillin and inoculated with staphylococci, which were incubated at 30°C for 24 h. The MIC was read as the lowest concentration of antibiotic which allowed no visible growth.
Pharmacokinetic study design. Six healthy male volunteers participated in this study after providing informed consent. They ranged in age from 22 to 23 years and averaged 74.3 ± 6.4 kg (mean ± standard deviation) in weight and 1.93 ± 0.10 m2in surface area; mean creatinine clearance was 108.4 + 14.9 ml/min. They were considered to be normal on the basis of medical history, renal and liver function tests, comnplete blood count, and urinalysis. A history of hypersensitivity to drugs was not present in any of the study subjects.
Teicoplanin was administered in a triple-crossover design at the following intravenous and intramuscular doses (strictly adjusted per kilogram of body weight): 3 and 6 mg/kg (in 20 ml of physiological saline) intravenously (i.v.) through a forearm vein as a slow (5-min) bolus injection, and 3 mg/kg (as 100 mg/ml saline solution) intramuscularly (i.m.), deep in the lateral gluteal region. The different drug regimens were randomized, and the interval between successive treatments was 2 to 3 weeks. Subjects fasted overnight and up to 2 h after drug administration in each segment of the study. In the morning of each study day, 200 ml of water was given orally to ensure adequate urine output, followed by more liquids ad libitum throughout the day. An indwelling butterfly needle was kept in a contralateral arm vein during the first 12 h and maintained patent by a minimum flushing dose of heparinsaline solution (100 IU/ml); later blood samples were collected each time by direct venal puncture.
Blood and urine collections. After the first 1 to 2 ml was discarded, 6-ml samples of blood were collected in lithiumheparin-coated tubes before drug administration (blank sample), at the end of the injection (5 min), and at 15, 30, and 45 min and 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 60, 72, 96 , and 102 h after drug administration. Blood samples were kept at 4°C before processing; plasma was separated within 1 h and stored at -70°C until assayed. Plasma was preferred to serum because it did not require clotting time.
Urine was collected before drug administration and 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96 , and 102 h after drug administration. Separate voidings were kept at 4°C during the longer collection periods; after collection, total volumes were measured, and 10-ml portions were stored at -700C pending analysis. Preliminary assays showed that teicoplanin was stable in urine at 4°C for at least 24 h and stable in either plasma or urine at -70°C for at least 2 weeks. All samples in this study were assayed within 1 week after collection.
Antibiotic assay. The concentrations of teicoplanin in plasma and urine samples were determined by an agar diffusion method with a hyperpermeable mutant B of Bacillus subtilis ATCC 6633 (provided by V. Arioli of Gruppo Lepetit, Milan). Antibiotic medium no. 2 (Oxoid) with 5% citrate buffer (46.4 ml of 0.2 M citric acid, 53.6 ml of 0.4 M Na2HPO4 [pH 5.2] ) was used for all bioassays. The seeded medium was poured into petri dishes and allowed to harden on a horizontally leveled support. Six wells (diameter, 4 mm) were cut out at equal distances in each plate. Plasma concentrations were assayed undiluted or, if necessary, diluted in human plasma; urine samples were diluted in saline as appropriate to obtain concentrations in the range of the standard curves. Samples of the administered teicoplanin solutions were stored and assayed under the same conditions. Each specimen was assayed in duplicate in opposite wells. After incubation at 36°C for 18 h, the inhibition zones were measured with a Fisher-Lilly zone reader. The antibiotic concentration was calculated from the mean zone diameter with the regression curve of the appropriate standard.
A teicoplanin preparation of certified potency was used as standard reference. Final concentratiotis of 32, 16, 8, 4, 2, 1, 0.5, and 0.25 ,ug/ml were prepared in human plasma for plasma samples and in saline for the assay of urine samples and of portions of the teicoplanin solutions for injection. Standards were assayed in quadruplicate. The regression lines were calculated from the mean zone diameters of each concentration with the following formula: log Y = a + bX, (Y = concentration in micrograms per milliliters; X = diameter in millimeters). The regression curves were calculated on at least five concentrations. The regression coefficients varied from 0.999 to 0.9994. The lowest reliable level to be measured was 0.25 p.g/ml. The mean recovery from six different samples of teicoplanin solution for injection was 96.6%, and the coefficient of variation was 0.048.
Pharmacokinetic analysis and calculations. After i.v.doses, curves for teicoplanin concentration in plasma showed a triexponential decay on a semilogarithmic graph. An open three-compartment model, with elimination from the central compartment, was found adequate to describe i.v. teicoplanin kinetics according to the following equation: Cp, = Pe-' + Ae-a' + Be-', where Cp, is the concentration in plasma at time t; wT, ox, and I are the exponential coefficients (slopes) during the three phases, with ,B representing the terminal disposition constant; P, A, and B are the intercept constants or concentrations of the exponential terms at zero time (6) . Estimates of these parameters were obtained graphically after refinement of these estimates by least-squares regression analysis on an HP-14C microcomputer. From these values, the other kinetic parameters were calculated by convential methods (9) : the volumes of distribution of the central compartment (V,) and of the fast (V2) and the slow (V3) equilibrating compartments; the intercompartment rate constants (k12, k2l, k13, k31), and the overall elimination constant (kel). The areas under the plasma concentrationtime curves (AUC) were calculated by the trapezoidal rule with extrapolation to infinity by the following equations (10) Safety tests. Subjects were monitored for general and local clinical signs and symptoms; pulse rate and blood pressure were measured before the start and at regular intervals during the first 2 h. During each study period, blood and urine analyses were carried out before and 96 h after each drug administration. The blood analysis comprised counts of erythrocytes, leukocytes (total and differential), and platelets and a blood chemistry consisting of serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase, total and direct bilirubin, blood urea nitrogen, uric acid, creatinine, and fasting blood glucose. Measurements of creatinine phosphokinase and of aldolase, as indicators for tissue destruction, were also obtained before and after the umes of distribution after the two i.v. doses were very similar, both for the central compartment (V1) as well as for the peripheral compartments (V2 and V"3). The rate constants for transfer into the peripheral compartments (k12, k13) were substantially higher than the rate constants for refiux into the central compartment (k21, k31) and the rate constant for elimination from the body (k10). The AUG after the 6-mg/kg dose was almost double of that after the 3-mg/kg dose.
Total body clearance (CUr) estimates were very similar for both doses with almost equally important renal clearance (CLR) and nonrenal clearance (CLNIO values. The cumulative urinary excretion rates of active compound in 0 to 102 h urine were 43 and 44%, respectively (Fig. 2) , and by extrapolating to infinity, about 54% of the administered i.v. doses may be recovered. If this amount is taken as 100% of the expected amount to be excreted, the actual figures can be transformed into percentages of this expected amount, and the half-life of the urinary excretion can be calculated. The time necessary to excrete 99% of the expected amount was 13 to 14 days for both i.v. doses. It explains why blank urines of the second and the third study period showed antibiotic activity. In the second period, starting 3 weeks after the first one, five out of six blank urines showed traces of teicoplanin ranging from 0.2 to 0.8 ,ug/ml. In the third period, starting 2 weeks after the second, all blank urines were positive for teicoplanin (1.0 to 2.5 ,ug/ml). However, in no instance were detectable concentrations found in blank plasma samples.
Kinetics after i.m. administration. The mean teicoplanin levels in plasma after i.m. administration are shown in Fig.  1 . The mean kinetic parameters are listed in Table 2 . Average peak level in plasma (7.1 ,ug/ml) was obtained after 2 h and the bioavailability factor (F) after i.m. administration, based on the ratios of AUC values, was 90.1% of the corresponding i.v. dose. The terminal half-life after i.m. administration (47.48 h) was almost identical with that after i.v. administration (47.35 h); so were the urinary excretion values (Fig. 2) , when the bioavailability factor was taken into account.
DISCUSSION
Our in vitro results agree very well with those of other authors (2, 5, 7, 8, 11, 14, 15, 18) . They show that teicoplanin is very active against all gram-positive cocci. In comparison with vancomycin, it is slightly more active against staphylococci but substantially more active against streptococci. More specifically, teicoplanin inhibited 100% of the enterococci at a concentration of 1 jxg/ml; in this study as well as in others, it was four-to eightfold more active than vancomycin and penicillin and two-to eightfold more active than ampicillin (2, 5, 7, 15) .
This study also showed that teicoplanin has excellent activity against different species of the viridans group of streptococci; all isolates were inhibited by a concentration of 0.12 ,ug/ml. Teicoplanin was generally four times more kg) will provide adequate levels in plasma over the entire 24-h period. Even the 24-h concentrations in plasma exceeding 2 ,ug/ml are well above the MICs for most viridans streptococci, enterococci, and staphylococci. Teicoplanin seems to be much better tolerated than vancomycin. Indeed, even after the i.v. bolus injection of 6 mg/kg (ca. 400 mg) in 20 ml of solution over 5 min (i.e., 80 mg/min), no significant changes were observed in either heart rate or blood pressure, and no subject experienced any abnormal sensations. In contrast, Krogstad et al. (13) reported that recipients of 1,000 mg of vancomycin in 500 ml of glucose over 30 min (i.e., 33 to 34 mg/min) experienced tachycardia, pruritus at the site of infusion, and generalized flushing. In one of these subjects, drug administration had to be stopped after 20 min because of nausea and a fall in blood pressure. Also in contrast to vancomycin, teicoplanin can be given i.m., although this route of administration was accompanied by a mild but long-lasting pain at the injection site which might be a problem in some individuals.
Because of its narrow spectrum, its bactericidal activity on gram-positive cocci, its good tolerability, and its interesting pharmacokinetic features, teicoplanin has potential importance as an alternative drug for long-term treatment of bacterial endocarditis or of chronic osteomyelitis. This antibiotic deserves further evaluation to establish its usefulness in clinical settings.
